Detection of cancer‐associated cachexia in lung cancer patients using whole‐body [ 18 F]FDG‐PET/CT imaging: A multi‐centre study
Journal of Cachexia, Sarcopenia and Muscle · 2024
DOI: 10.1002/jcsm.13571 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2024. Verfasst von Daria Ferrara und 15 weiteren Autor:innen. Beteiligte Einrichtung: QIMP Team, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Cachexia, Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Lung Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Commission Research Directorate-General, Austrian Science Fund, Innovation Fund Denmark.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Cancer‐associated cachexia (CAC) is a metabolic syndrome contributing to therapy resistance and mortality in lung cancer patients (LCP). CAC is typically defined using clinical non‐imaging criteria. Given the metabolic underpinnings of CAC and the ability of [ 18 F]fluoro‐2‐deoxy‐D‐glucose (FDG)‐positron emission tomography (PET)/computer tomography (CT) to provide quantitative information on glucose turnover, we evaluate the usefulness of whole‐body (WB) PET/CT imaging, as part of the standard diagnostic workup of LCP, to provide additional information on the onset or presence of CAC.
Methods
This multi‐centre study included 345 LCP who underwent WB [ 18 F]FDG‐PET/CT imaging for initial clinical staging. A weight loss grading system (WLGS) adjusted to body mass index was used to classify LCP into ‘No CAC’ (WLGS‐0/1 at baseline prior treatment and at first follow‐up: N = 158, 51F/107M), ‘Dev CAC’ (WLGS‐0/1 at baseline and WLGS‐3/4 at follow‐up: N = 90, 34F/56M), and ‘CAC’ (WLGS‐3/4 at baseline: N = 97, 31F/66M). For each CAC category, mean standardized uptake values (SUV) normalized to aorta uptake () and CT‐defined volumes were extracted for abdominal and visceral organs, muscles, and adipose‐tissue using automated image segmentation of baseline [ 18 F]FDG‐PET/CT images. Imaging and non‐imaging parameters from laboratory tests were compared statistically. A machine‐learning (ML) model was then trained to classify LCP as ‘No CAC’, ‘Dev CAC’, and ‘CAC’ based on their imaging parameters. SHapley Additive exPlanations (SHAP) analysis was employed to identify the key factors contributing to CAC development for each patient.
Results
The three CAC categories displayed multi‐organ differences in . In all target organs, was higher in the ‘CAC’ cohort compared with ‘No CAC’ ( P < 0.01), except for liver and kidneys, where in ‘CAC’ was reduced by 5%. The ‘Dev CAC’ cohort displayed a small but significant increase in of pancreas (+4%), skeletal‐muscle (+7%), subcutaneous adipose‐tissue (+11%), and visceral adipose‐tissue (+15%). In ‘CAC’ patients, a strong negative Spearman correlation (ρ = −0.8) was identified between and volumes of adipose‐tissue. The machine‐learning model identified ‘CAC’ at baseline with 81% of accuracy, highlighting of spleen, pancreas, liver, and adipose‐tissue as most relevant features. The model performance was suboptimal (54%) when classifying ‘Dev CAC’ versus ‘No CAC’.
Conclusions
WB [ 18 F]FDG‐PET/CT imaging reveals groupwise differences in the multi‐organ metabolism of LCP with and without CAC, thus highlighting systemic metabolic aberrations symptomatic of cachectic patients. Based on a retrospective cohort, our ML model identified patients with CAC with good accuracy. However, its performance in patients developing CAC was suboptimal. A prospective, multi‐centre study has been initiated to address the limitations of the present retrospective analysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- QIMP Team, Medical University of Vienna, Vienna, Austria.
- Division of Nuclear Medicine, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
- Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany.
- Department of Respiratory Medicine, University Hospital Leipzig, Leipzig, Germany.
- Department of Endocrinology, University Hospital Leipzig, Leipzig, Germany.
ORCID-Profile: Daria Ferrara, Armin Frille
Förderung
- European Commission Research Directorate-General
- Austrian Science Fund
- Innovation Fund Denmark
- Regione Toscana
- Saxon State Ministry for Science, Culture and Tourism (Germany)
- Federal Ministry of Education and Research (BMBF), Germany
- Mitteldeutsche Gesellschaft für Pneumologie (MDGP) e.V.
- Medical Faculty, University of Leipzig
Zitieren
APA
Ferrara, D., Abenavoli, E. M., Beyer, T., Gruenert, S., Hacker, M., Hesse, S., Hofmann, L., Pusitz, S., Rullmann, M., Sabri, O., Sciagrà, R., Sundar, L. K. S., Tönjes, A., Wirtz, H., Yu, J., & Frille, A. (2024). Detection of cancer‐associated cachexia in lung cancer patients using whole‐body [ 18 F]FDG‐PET/CT imaging: A multi‐centre study. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.13571
Vancouver
Ferrara D, Abenavoli EM, Beyer T, Gruenert S, Hacker M, Hesse S, et al. Detection of cancer‐associated cachexia in lung cancer patients using whole‐body [ 18 F]FDG‐PET/CT imaging: A multi‐centre study. Journal of Cachexia, Sarcopenia and Muscle. 2024. doi:10.1002/jcsm.13571
BibTeX
@article{Ferrara2024,
author = {Ferrara, Daria and Abenavoli, Elisabetta M and Beyer, Thomas and Gruenert, Stefan and Hacker, Marcus and Hesse, Swen and Hofmann, Lukas and Pusitz, Smilla and Rullmann, Michael and Sabri, Osama and Sciagrà, Roberto and Sundar, Lalith Kumar Shiyam and Tönjes, Anke and Wirtz, Hubert and Yu, Josef and Frille, Armin},
title = {Detection of cancer‐associated cachexia in lung cancer patients using whole‐body [ 18 F]FDG‐PET/CT imaging: A multi‐centre study},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2024},
doi = {10.1002/jcsm.13571}
}
EUVIMED